Pharmacovigilance Update;Pharmacovigilance Update

Revue Medicale Suisse

Volumn 6, Issue 232, 2010, Pages 128-131

  Livio, Françoise ^a   Ivanyuk, Anton ^a   Biollaz, Jérôme ^a   Rothuizen, Laura ^a   Buclin, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; CLOPIDOGREL; EFALIZUMAB; ERLOTINIB; ETRAVIRINE; EXENDIN 4; INSULIN GLARGINE; MYCOPHENOLIC ACID; NATALIZUMAB; PROTON PUMP INHIBITOR; RITUXIMAB; SITAGLIPTIN;

ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SURVEILLANCE PROGRAM; EYE DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PANCREATITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PURE RED CELL ANEMIA; RASH; REVIEW;

HUMANS; SAFETY-BASED DRUG WITHDRAWALS;

EID: 76749084366     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Zhang Z, Schmitt J, Wozel G, Kirch W. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin 2009;104:125-36.
2. Engelen W, Verpooten GA Van der Planken M, et al. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol 2003:60:119-24.
3. Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with eriotinib treatment Cornea 2009;28:706-7.
4. Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from eriotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008;66:155-62.
5. Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009;48:1123-8.
6. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27.
7. Weise WJ, Sivanandy MS, Block CA Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care 2009;32:e22-3.
8. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52:1732-44.
9. Jonasson JM, Ljung R, Talbäck M, et al. Insulin glargine use and short-term incidence of malignancies - a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-54.
10. Currie CJ, Poole CD, Gale EA The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
11. The SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-65.
12. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised open-label study. Diabetologia 200952:1971-3.
13. * www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/ CON057141
14. ** Tefferi A, Stone RM. Iron chelation therapy in myelodysplasia syndrome - Cui bono? Leukemia 2009;23:1373.
15. Steensma DP. Myelodysplasia paranoia: Iron as the new radon. Leuk Res 2009;33:1158-63.
16. Baldwin CM, Plosker GL Aliskiren/hydrochlorothiazide combination: In mild to moderate hypertension. Drugs 2009;69:833-41.
17. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
18. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and dopidogrel. CMAJ 2009;180:713-8.
19. Stanek EJ, Aubert RE, Rockhart DA et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with dopidogrel following coronary stenting: The Clopidogrel Medco Outcomes Study, www.scai.org/drltl.aspx?PAGE-ID=5870
20. Small DS, Farid NA Ernest CS, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and dopidogrel. Curr Med Res Opin 2008;24:2251-7.